These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26375670)

  • 1. Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
    Chi MS; Lee CY; Huang SC; Yang KL; Ko HL; Chen YK; Chung CH; Liao KW; Chi KH
    Oncotarget; 2015 Oct; 6(30):29808-17. PubMed ID: 26375670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
    Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
    Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
    Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
    Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
    Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results.
    Ghigi G; Micera R; Maffione AM; Castellucci P; Cammelli S; Ammendolia I; Nanni C; Barbieri E; Grassetto G; Fanti S; Rubello D
    In Vivo; 2009; 23(1):105-10. PubMed ID: 19368133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
    Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
    Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
    Kasper B; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Haberkorn U; Ho AD; Egerer G
    Onkologie; 2008 Mar; 31(3):107-12. PubMed ID: 18322413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
    Kasper B; Schmitt T; Wuchter P; Ho AD; Egerer G
    Dtsch Med Wochenschr; 2009 Sep; 134(39):1922-6. PubMed ID: 19760551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
    Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
    Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.
    Moon SY; Joo KR; So YR; Lim JU; Cha JM; Shin HP; Yang YJ
    Clin Nucl Med; 2013 Oct; 38(10):778-83. PubMed ID: 24107806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early metabolic change in (18)F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients' survival: PEACH study.
    Tanaka Y; Ueda Y; Egawa-Takata T; Matsuzaki S; Kobayashi E; Yoshino K; Enomoto T; Tatsumi M; Kimura T
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):121-6. PubMed ID: 26659584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
    Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
    J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.